CoChat

Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders

Open access
Sagar, M., Bertilsson, L., Stridsberg, M., Kjellin, A., Mårdh, S., Seensalu, R. · 2000 · Alimentary Pharmacology & Therapeutics
Cited by 38

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background: The polymorphic enzyme CYP2C19 is of importance for the metabolism and effects of omeprazole during short‐term treatment. Aim: To investigate the relationship between CYP2C19 genotype and the effects of long‐term omeprazole treatment. Material and methods: A total of 180 patients with acid related disorders were genotyped for wild type and mutated CYP2C19 alleles by allele‐specific PCR amplification. Gastrin and chromogranin A were assessed by radioimmunoassays, and pepsinogen I and H. pylori serology were assessed by ELISA methods. Results: In 108 of the patients, who received a single dose of 20 mg omeprazole, there was no difference in gastrin and chromogranin A concentrations between the three CYP2C19 genotypes. In 72 patients on long‐term treatment (> 1 year) with 20 mg omeprazole daily, serum gastrin as well as plasma chromogranin A concentrations (mean ± s.e.) were both about threefold higher in the wild type/mutated (52.1 ± 7.6 p M and 7.3 ± 1.3 n M (n=19), respectively) compared to wild type/wild type (14.7 ± 0.9 p M and 2.5 ± 0.1 n M (n=52), respectively; both comparisons P=0.0001). In a single mutated/mutated patient on long‐term treatment, both gastrin and chromogranin A were high (88 p M and 13.7 n M, respectively). Serum pepsinogen I concentration was significantly lower in wild type/mutated (n=19) patients on long‐term treatment, compared with the corresponding wild type/wild type (n=49) group (147 ± 19 μg/L vs. 193 ± 12 μg/L, P=0.04). Conclusion: Patients with one (and probably also with two) mutated CYP2C19 allele(s) on long‐term treatment with omeprazole had significantly affected serum gastrin and pepsinogen I and plasma chromogranin A concentrations compared with patients with two normal alleles. This indicates that changes in gastric mucosal morphology during omeprazole treatment might be dependent upon the degree of the individual’s capacity to metabolize omeprazole.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2000.00835.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 38

Metadata

Authors
Sagar, M., Bertilsson, L., Stridsberg, M., Kjellin, A., Mårdh, S., & Seensalu, R.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2000-11-27
Volume
14
Issue
11
Pages
1495-1502
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2081846604
Cited by
38
References
1
FWCI
1.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. https://app.cochat.ai/papers/10.1046/j.1365-2036.2000.00835.x
The paper
Sagar, M., Bertilsson, L., Stridsberg, M., Kjellin, A., Mårdh, S., & Seensalu, R. (2000). Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2000.00835.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.